{"url_path":"/sec/slno/8-k/2026-05-18/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","accession_number":"0001193125-26-228016","cik":"0001484565","ticker":"SLNO","issuer_name":"SOLENO THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","primary_entity_key":"0001484565","primary_entity_name":"SOLENO THERAPEUTICS INC"},"word_count":354,"has_tables":true,"body_markdown":"Item 5.02.\n\nDeparture of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers\n\nThe information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.\n\nIn accordance with the terms of the Merger Agreement, each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair\n\nand Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors and all committees thereof effective as of the Effective Time. Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company, in each case, as of the Effective Time. The director resignations were tendered in connection with the Merger and were not a result of any disagreement between the Company and the directors on any matter relating to the Company’s operations, policies or practices.\n\nIn accordance with the terms of the Merger Agreement, (i) each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer of the Company, in each case, effective as of the Effective Time. Following the Effective Time, the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).\n\nInformation about Matthew C. Abernethy and Darin M. Lippoldt is contained in the Offer to Purchase, filed by Purchaser and Parent as [Exhibit (a)(1)(A](http://www.sec.gov/Archives/edgar/data/914475/000119312526162715/d140647dex99a1a.htm)) to the Tender Offer Statement on Schedule TO, originally filed with the SEC on [April 20, 2026](http://www.sec.gov/Archives/edgar/data/914475/000119312526162715/d140647dsctot.htm), which information is incorporated herein by reference.\n\nThe foregoing director and officer resignations were tendered in connection with the Merger and were not a result of any disagreement between the Company and such former directors and officers on any matter relating to the Company’s operations, policies or practices."}